scholarly journals Moist exposed burn ointment: Role of alternative therapy in the management of partial-thickness burns

2010 ◽  
Vol 76 (4) ◽  
pp. 415 ◽  
Author(s):  
Sanjay Saraf
Author(s):  
Justin CR Wormald ◽  
Ryckie G Wade ◽  
Jonathan A Dunne ◽  
Declan P Collins ◽  
Abhilash Jain

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 370
Author(s):  
Umair Iqbal ◽  
Ravirajsinh N. Jadeja ◽  
Harshit S. Khara ◽  
Sandeep Khurana

Hepatic encephalopathy (HE) is a common neurological consequence in patients with cirrhosis and has a healthcare burden of USD 5370 to 50,120 per patient annually. HE significantly hampers the quality of life and is a major cause of morbidity and mortality. Patients with cirrhosis are at a high risk for protein-calorie malnutrition due to altered metabolism. Current evidence has changed the old belief of protein restriction in patients with cirrhosis and now 1.2 to 1.5 g/kg/day protein intake is recommended. Case series and studies with small numbers of participants showed that a vegetarian protein diet decreases the symptoms of HE when compared to a meat-based diet, but the evidence is limited and requires further larger randomized controlled trials. However, vegetable or milk-based protein diets are good substitutes for patients averse to meat intake. Branch chain amino acids (BCAA) (leucine, isoleucine and valine) have also been shown to be effective in alleviating symptoms of HE and are recommended as an alternative therapy in patients with cirrhosis for the treatment of HE. In this review, we provide an overview of current literature evaluating the role of protein intake in the management of HE in cirrhosis.


2011 ◽  
Vol 46 (9) ◽  
pp. 1759-1763 ◽  
Author(s):  
Aaron P. Lesher ◽  
Ryan H. Curry ◽  
Jill Evans ◽  
Valerie A. Smith ◽  
Michael T. Fitzgerald ◽  
...  

Burns ◽  
2019 ◽  
Vol 45 (4) ◽  
pp. 876-890 ◽  
Author(s):  
Quentin Frew ◽  
Hans-Oliver Rennekampff ◽  
Peter Dziewulski ◽  
Naiem Moiemen ◽  
Tobias Zahn ◽  
...  

Author(s):  
Mehrdad Mirzarahimi ◽  
Ramin Emamzadeghan ◽  
Afsaneh Enteshari Moghaddam ◽  
Narges Falsafi

Background: Patent ductus arteriosus (PDA) is a common cause of morbidity and mortality among premature infants that affects more than 40% of them. PDA treatment includes medical and surgical treatment. Most drugs used to block PDA are cyclooxygenase inhibitors (ibuprofen and indomethacin). The role of paracetamol as an alternative therapy in PDA ligation has been considered in recent years due to the potential side effects of cyclooxygenase inhibitors.Methods: Patients in the first group were treated with intravenous paracetamol at a dose of 15 mg/kg every 6 hours for three days and the second group was treated with intravenous ibuprofen at a daily dose of 10 mg/kg daily and 5 mg/kg for the second and third days. At the end of the treatment period (day 3), they underwent echocardiography again. If the echocardiographic findings indicated no closure of the arterial duct, patients were treated with the aforementioned drug for another period and rechecked at the end of the third day, and at each stage required information was collected.Results: Arterial duct closure in paracetamol group was 96.7% and in ibuprofen group was 100%. The effects of both paracetamol and ibuprofen were similar in terms of renal parameters but in terms of effects on liver parameters. The effect of paracetamol on all liver parameters except aspartate transaminase (AST) was significant, but ibuprofen was able to affect only bilirubin among liver parameters and had no significant effect on both AST and alanine aminotransferase, parameters.Conclusions: Results showed that both paracetamol and ibuprofen are effective in treating of PDA and had similar impact.


Sign in / Sign up

Export Citation Format

Share Document